Mixed-meal tolerance, arginine stimulation tests reproducible across glucose tolerance states
MONDAY, Aug. 1, 2016 (HealthDay News) — Standardized mixed-meal tolerance tests (MMTT) and arginine stimulation tests (AST) provide reproducible measures of β-cell function (BCF) across glucose tolerance states, according to a study published online July 12 in Diabetes Care.
Sudha S. Shankar, M.D., from Eli Lilly and Co. in Indianapolis, and colleagues characterized the responses to, and reproducibility of, standardized methods of in vivo BCF. Participants with normal glucose tolerance (NGT, 23 participants), prediabetes (PDM, 17 participants), and type 2 diabetes mellitus (T2DM, 22 participants) underwent two standardized MMTT, two standardized AST, and one frequently sampled intravenous glucose tolerance test (FSIGT).
The researchers found that from the MMTT, insulin secretion in T2DM was more than 86 percent lower than in NGT or PDM. There was a decrease in insulin sensitivity (Si) from NGT to PDM (~50 percent) to T2DM (93 percent lower). At basal glucose and during hyperglycemia, insulin secretory response to arginine was lower in T2DM compared with NGT and PDM in the AST. FSIGT showed decreases across populations in both insulin secretion and Si; no significant difference was observed in Si for PDM and T2DM populations. Reproducibility was generally good for the MMTT and very good for the AST.
“Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, several of which provided funding for the study.
Abstract
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
